Background: Quadrivalent meningococcal conjugate vaccines (MenACWY) were developed to offer long-term protection against invasive disease caused by serogroups A, C, W, and Y. Reduced MenACWY effectiveness within 5 years after primary vaccination (likely due to declining bactericidal antibody titers) has been described, particularly with respect to C and Y disease in the United States. We evaluated the safety and immunogenicity of a single booster dose of quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine (MenACWY-D) in adolescents and adults who received a previous dose 4-6 years earlier.
Introduction
The aerobic gram-negative diplococcus Neisseria meningitidis is a leading cause of bacterial meningitis, with the most common presentation of invasive meningococcal disease (IMD) being purulent meningitis [1] . Meningococcal sepsis without meningitis occurs in 5-20% of cases of IMD [1] . The overall case-fatality ratio for meningococcal disease is 10-15%, while meningococcal sepsis is fatal in 40% of cases [1] . Up to 10% of adolescents and adults are transient asymptomatic carriers of meningococci, and transmission is primarily through the exchange of nasopharyngeal secretions from colonized or infected individuals [1] . Although at least 12 basis of structural differences in the capsular polysaccharide, only five (A, B, C, W, and Y) have been primarily responsible for IMD worldwide, while a sixth serogroup (X) has emerged since 2006 as an important cause of IMD in Africa [1] [2] [3] [4] .
Prior to the introduction of the serogroup A meningococcal polysaccharide-tetanus toxoid conjugate vaccine in sub-Saharan Africa in 2010, an estimated 1.2 million new cases of IMD occurred globally each year in both endemic and epidemic forms, resulting in approximately 135,000 deaths [5] . In the United States, provisional surveillance estimates for 2014 indicate a total of 450 cases of meningococcal disease (0.14 cases per 100,000 population), resulting in an estimated 65 deaths (0.02 deaths per 100,000 population) [6] . Incidence of meningococcal disease in the United States varies according to age, with infants younger than one year of age being at the greatest risk, followed by persons 16 through 21 years of age [7, 8] . The financial burden imposed by IMD on the healthcare system in the United States is substantial, as documented by a population-based observational study that reported the cost per hospitalization due to meningococcal meningitis as having risen from $18,417 in 1997 to $55,251 in 2010 [9] . The public health impact and economic burden of meningococcal infection underscore the need for effective vaccines and their optimal use.
Two quadrivalent (ACWY) conjugate vaccines (one conjugated to diphtheria toxoid and the other to a non-toxic mutant of diphtheria toxin [CRM 197 ]), one quadrivalent (ACWY) polysaccharide vaccine, one bivalent (CY) conjugate vaccine, and two serogroup B vaccines are currently available for use in the United States for active immunization against meningococcal disease in various age groups [7, 10] . Conjugate vaccines are effective across a wide age range, including children younger than 2 years of age, and offer an advantage over unconjugated polysaccharide vaccines in that they elicit T-cell-dependent responses characterized by the generation of memory B cells that drive booster antibody responses to exposure or to subsequent doses of conjugate vaccine [11] . Moreover, unlike unconjugated vaccines, they do not induce immunologic hyporesponsiveness, a phenomenon marked by an attenuated antibody response to subsequent antigenic exposure that results from the depletion of the memory B-cell pool [11] . A recent comparison of the population structure of invasive N. meningitidis in the United States before (2000) (2001) (2002) (2003) (2004) (2005) and after (2006-2010) the introduction of conjugate vaccines has revealed substantial differences in the serogroup distribution between the two periods; however, vaccine-driven serogroup replacement was not evident [12] .
Quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine (MenACWY-D), which is currently registered in more than 50 countries, was first licensed in the United States in 2005 for active immunization against IMD in adolescents and adults 11 through 55 years of age, in 2007 for use in children two through 10 years of age, and in 2011 for use in infants and toddlers nine through 23 months of age [7] . Although protective levels of antibodies have been documented up to three years following primary vaccination of adolescents with MenACWY-D [13] , diminished vaccine effectiveness against C and Y disease in the United States has been described. This has been attributed to declining serum bactericidal assay (SBA) antibody titers over time, which have been observed in children first vaccinated at 2 years of age and in adolescents [7, [13] [14] [15] [16] [17] . In 2010, the Advisory Committee on Immunization Practices (ACIP) in the United States recommended that a booster dose of MenACWY be administered at age 16 years if the primary dose had been administered at age 11 or 12 years, or at age 16 through 18 years if the primary dose had been administered at age 13 through 15 years [18] . In light of these recommendations, we conducted study MTA77, a phase 2, openlabel study to determine the safety and immunogenicity of a single booster dose of MenACWY-D in persons who had received their first dose 4-6 years previously.
Methods

Study design
This phase 2, open-label study was conducted between September 2011 and July 2012 at 15 centers in the United States and evaluated the safety and immunogenicity of a single booster dose of MenACWY-D 4-6 years after prior vaccination in persons first vaccinated at P11 years of age. The study was conducted in compliance with the Edinburgh revision of the Declaration of Helsinki [19] and followed International Committee on Harmonisation (ICH) guidelines for Good Clinical Practice (GCP) [20] . Written informed consent was provided by participants or their parent(s) or legal guardian(s) before enrollment. The study is registered at ClinicalTrials.gov (NCT01442675).
Participants
Participants were <56 years of age and had received MenACWY-D within 4-6 years prior to study enrollment, at age P11 years. Exclusion criteria included a history of documented IMD, receipt of any meningococcal vaccine other than a single dose of MenACWY-D 4-6 years prior to enrollment, receipt of any vaccine within 30 days before receiving study vaccine (except for influenza vaccine, which could be administered up to 15 days before study vaccine), chronic illness that could interfere with study conduct or completion, history of Guillain-Barré syndrome, potential contraindications for intramuscular (IM) administration (thrombocytopenia, bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding vaccination), or receipt of antibiotic(s) within 72 h prior to the first blood draw. Temporary exclusion criteria included moderate or severe acute illness, infection, or febrile illness (temperature P38.0°C); enrollment of prospective participants with these conditions was delayed until the condition was resolved. pyrogen-and preservative-free phosphate-buffered physiological saline. The vaccine was administered on Day 0 as a single 0.5-mL IM injection in the deltoid region, using a needle of appropriate length (at the discretion of the investigator) to ensure IM delivery.
Study vaccine and administration
Immunogenicity objectives and endpoints
The primary immunogenicity objective was to evaluate antibody responses to the four serogroups (A, C, W, and Y), measured by serum bactericidal assay using human complement (hSBA), which was performed as previously described [21] . The hSBA determines the concentration of group-specific functional antibodies against meningococci, and titers P1:4 have been directly correlated to protection against meningococcal disease [22, 23] . The endpoint for this objective was the proportion of participants achieving hSBA antibody titers P1:8 to the four serogroups in serum specimens collected 28 (window, 21-35) days postvaccination. The secondary immunogenicity objective was to evaluate antibody (memory) responses by hSBA to the four serogroups in serum specimens collected 6 (window, 5-7) days postvaccination in a subset of 120 participants. The endpoint for this objective was the proportion of participants achieving hSBA antibody titers P1:8 to the four serogroups.
Safety objectives and endpoints
The safety objective was to describe the rates of immediate adverse events (AEs), solicited injection-site and systemic reactions, unsolicited nonserious AEs, and serious adverse events (SAEs) following vaccination. Safety endpoints included the occurrence, time to onset, duration, and intensity of: immediate AEs occurring within 20 min after vaccination; solicited injection-site and systemic reactions occurring up to 7 days after vaccination; unsolicited nonserious AEs occurring between Day 0 and Day 28; and any SAE occurring within 6 months post-vaccination. Relationship to vaccination was assessed for unsolicited systemic AEs that occurred within 20 min of vaccination, unsolicited nonserious AEs occurring between Day 0 and Day 28, and SAEs; AEs involving the injection-site were presumed to be related to vaccination. AEs considered related to vaccination were termed adverse reactions (ARs). Adverse events were defined using preferred terms from the Medical Dictionary for Regulatory Activities (MedDRA) version 14.0.
Serologic evaluations
The hSBA was performed in the sponsor's laboratory according to established procedures that have been previously described [21] . The lower limit of quantitation of the hSBA was a titer of 1:4.
Statistical methods and determination of sample size
All statistical analyses were performed using SAS Ò software (Version 9.1 or later; SAS Institute, Inc., Cary, North Carolina, USA). Continuous demographic variables are presented by summary statistics (eg, mean and standard deviation [SD], minimum, and maximum) and categorical variables are presented by frequency distributions (eg, frequency counts, percentages, and their 95% confidence intervals [CIs] calculated using the exact method). The hypothesis for the primary endpoint was that the proportion of participants achieving an hSBA antibody titer P1:8 following a booster dose of MenACWY-D vaccine would be P85% for each serogroup. The hypothesis was considered to be supported if the lower one-sided 95% confidence limit (CL) for the observed proportion was P85%, calculated using the exact binomial (Clopper-Pearson) method, quoted by Newcombe (ie, using the inverse of the beta integral with SAS) [24] . A sample size of 750 evaluable participants was estimated to provide at least 95% power to achieve the primary hypothesis for each serogroup, assuming the true response was >90%, and assuming independent immune responses to each serogroup among and within participants. In addition, with 834 participants enrolled, there was a probability of approximately 95% to observe at least one AE, given a true incidence as low as 0.4%. No imputation for missing data was performed. For the secondary endpoint-the proportion of persons with hSBA titers P1:8 and P1:4 in the subset of 120 participants evaluated 6 (window, 5-7) days following vaccination-95% CIs of point estimates were calculated assuming proportions follow a binomial distribution, using the exact method.
Calculation of geometric mean titers (GMTs) assumed that the Log 2 transformation of the titers/data followed a normal distribution. The mean and the 95% CI were first calculated on Log 2 (titers/data) using the usual calculation for the normal distribution (Student's t distribution with n-1 degree of freedom), then antilog transformations were applied to the results of calculations in order to provide geometric means and their 95% CIs.
Immunogenicity analyses were conducted using the perprotocol analysis set (PPAS), which comprised participants who received the dose of study vaccine and complied with all protocol-specified requirements and procedures. The full analysis set (FAS) (ie, the intent-to-treat population) consisted of all participants who received a dose of study vaccine and had a postvaccination serology result. Safety analyses were conducted using the safety analysis set, which comprised all participants who received the study vaccine and for whom safety data were available.
Results
Demographic characteristics and disposition of participants
A total of 834 participants enrolled and 822 (98.6%) completed the study. Most participants were white (90.0%), 52% were female, and the mean (SD) age was 17.8 (3.2) years (Table 1) . Reasons for discontinuing the study included noncompliance (n = 6 [0.7%]), loss to follow-up (n = 2 [0.2%]), and voluntary withdrawal of consent (n = 4 [0.5%]) ( Table 2 ). Of 834 enrolled participants, 831 were included in the safety analysis set, 820 were included in the FAS, and 781 were included in the PPAS (Table 2) .
Immunogenicity evaluations
The results from the PPAS are presented; the FAS produced similar results (data not shown).
Prior to booster vaccination, the percentages of participants with an hSBA titer P1:8 were 64.5%, 44.2%, 68.5%, and 38.7% for serogroups A, C, W, and Y, respectively. More than 98% of participants had hSBA antibody titers P1:8 for all serogroups by Day 6 post-vaccination and >99% achieved this threshold by Day 28 (Table 3) . At Day 28, the lower limit of the one-sided 95% CL was P85% for serogroups A, C, W, and Y, meeting the primary hypothesis-specified proportion. Geometric mean titers for all antigens increased substantially postvaccination ( Table 4) . The geometric mean ratios of post-vaccination:pre-vaccination titers at 28 days postvaccination ranged from 47.2 (serogroup A) to 209.1 (serogroup Y).
In additional analyses of the primary immunogenicity endpoint, there were no material differences by age (15-18 years vs. P19 years), race (white vs. non-white), or gender (data not shown).
Safety evaluations
Solicited reactions were reported by 76.4% of participants (Table 5 ). Most began within 3 days post-vaccination, resolved within 1-3 days, and were grade 1 or grade 2 in intensity. The most common solicited injection-site reaction was pain, which occurred in 60.2% of participants. The most common solicited systemic reactions were myalgia (42.8%), followed by headache (38.6%) and malaise (29.4%).
One immediate AE of grade 1 dizziness occurred in one participant within 20 min of vaccination. Unsolicited AEs were reported in 245 (29.5%) participants (Table 6 ). The most commonly reported unsolicited AEs were nasopharyngitis and headache (each reported in 24 [2.9%] of participants). Most unsolicited AEs were grade 1 or 2 in intensity. Unsolicited ARs were reported in 14 (1.7%) of participants. ARs reported in more than 1 participant included injection-site hematoma (n = 3; 0.4%), injection-site pruritus (n = 3; 0.4%), and vomiting (n = 2; 0.2%). .2) a Three enrolled participants were not included the safety analysis set because they were not vaccinated.
b Eleven enrolled participants were not included in the FAS because they did not provide a post-vaccination blood sample. n, number of participants with hSBA titer P1:8 dilution; M, number of participants with available data; CI, confidence interval; CL, confidence limit. a The primary hypothesis tested was that the lower limit of the one-sided 95% CL was P85%. M, number of participants with data available; GMT, geometric mean titer; CI, confidence interval; GM, geometric mean.
Eleven participants reported at least one SAE during the 6-month follow-up period. Two SAEs of bronchitis and suicidal ideation occurred during the first 28 days of the study; both participants recovered without sequelae. All SAEs were considered to be unrelated to vaccination. No deaths occurred during the study.
There were no material differences in the frequencies of solicited AEs, unsolicited nonserious AEs, or SAEs by age (15-18 years vs. P19 years), race (white vs. non-white), or gender (data not shown).
Discussion
This study demonstrated the safety and immunogenicity of booster vaccination with MenACWY-D among adolescents and adults 4-6 years after prior vaccination. Robust bactericidal responses were observed for all vaccine serogroups. As early as Day 6, >98% of trial participants achieved hSBA titers P1:8, consistent with an anamnestic response. By Day 28, >99% of participants had hSBA titers P1:8. As further evidence of the robust memory response associated with booster vaccination with MenACWY-D, GMTs increased up to 100-fold within 6 days post-vaccination and up to 200-fold within 28 days.
Moreover, booster vaccination 4-6 years after the primary dose revealed no apparent safety concerns. Overall, rates of solicited reactions were comparable to those seen among adolescents and adults who received a primary dose of MenACWY-D in previous studies [25] . Rates of SAEs were low and none were considered vaccine-related.
The findings of this study are consistent with the findings of two previous studies assessing MenACWY-D booster vaccination. Keyserling and colleagues also observed that MenACWY-D safely induced robust booster responses in healthy adolescents who were primed 3 years beforehand [13] . Unpublished study MTA62 (NCT00700713) demonstrated that MenACWY-D was also safe and induced robust booster responses in a younger cohort, children 4-5 years of age who had received one or two doses 3 years earlier as infants and toddlers [26] . Of note, the serogroup-specific GMTs observed after booster vaccination in the current study population (median age: 17.1 years) were approximately 3-to 10-fold lower than those observed in the Keyserling et al. study population (median age: 17.0 years at time of booster vaccination). However, the Keyserling et al. study used an SBA with baby rabbit sera as the complement source, which generally results in higher SBA titers compared to the hSBA, the assay that was used in the current study [27] . This underscores the notion that comparison of SBA titers across different studies should generally be avoided since such comparisons are only valid when serum specimens from the same study population are assayed together, using a single complement source.
Although an earlier study of MenACWY-D in adolescents had demonstrated the persistence of bactericidal activity up to 3 years following initial vaccination [13] , waning of antibody levels over time has been documented [14] [15] [16] [17] . Findings from the current study also suggest waning antibody levels after primary MenACWY-D vaccination, given the relatively low GMTs that were observed immediately prior to booster vaccination. Of note, GMTs and the proportion of participants with hSBA titers P1:8 before vaccination were lower or trended lower for serogroups C and Y compared to serogroups A and W. In contrast, other studies either demonstrated greater or a trend toward greater antibody persistence following MenACWY-D for serogroups C and Y compared to serogroup A or W [13, 28] . These serogroup-specific differences in antibody persistence within the same study may be related to differences in natural exposure to cross-reacting polysaccharide antigens since antibody decay usually follows a predictable slope in the absence of other modifying events.
Waning immunity after primary vaccination notwithstanding, the current study demonstrated that a subsequent dose of MenACWY-D was effective in inducing a robust booster response for all vaccine serogroups. The observed antibody responses support current recommendations of the ACIP that in the US a booster dose be administered to all persons aged 16-18 years if the primary dose was administered before the sixteenth birthday [7] . The evi- n, number of participants with event; AE, adverse event; AR, adverse reaction; CI, confidence interval. Grade 3 for significant interference or prevention of daily activity.
dence of primary protection as demonstrated in earlier studies of infants and toddlers [21] and adolescents [13] and the finding of robust booster responses at least 3-6 years after priming suggest that substantial public health benefits may accrue from the primary and booster use of MenACWY-D. In fact, between introduction of the vaccine and 2012-2013, there had been an 80% reduction in the incidence of serogroup C, Y, and W disease among U.S. adolescents, the population that is the target of the U.S. immunization program [8] . As a conjugate vaccine, MenACWY-D offers substantial benefits, including the potential for reducing nasopharyngeal carriage of meningococci [29] , the induction of immunologic memory, and the ability to avoid immunological hyporesponsiveness [11] . The latter characteristic may particularly benefit those who require repeated meningococcal vaccination, including immunocompromised persons, elderly individuals, previously vaccinated travelers returning to areas where IMD is endemic, and persons at prolonged increased risk for IMD (eg, microbiologists working with meningococcal isolates).
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